CAMBRIDGE, Mass., (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 6,000,000 shares of its common stock at a public offering price of $31.25 per share, before deducting underwriter discounts and commissions and estimated offering expenses. Gross proceeds from the offering are expected to be approximately $187.5 million. Editas Medicine has granted the underwriter a 30-day option to purchase up to an additional 900,000 shares of common stock on the same terms and conditions. All of the shares in the offering are to be sold by Editas Medicine. The offering is expected to close on or about June 26, 2020, subject to customary closing conditions.

Morgan Stanley is acting as sole book-running manager for the offering.

About Editas Medicine

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.